For 25 years, Morunda has been interviewing leaders in Japan’s pharmaceutical and medical device industry. Most country managers typically come from a commercial background, rooted in sales and marketing. It’s rare to find country managers who come from finance or…
HOME > BUSINESS
BUSINESS
- Ohara’s Cancer Med Erwinase Reaches Japan Market Over 6 Years after Approval
June 15, 2023
- Chugai Files NDA for PNH Drug Crovalimab in Japan
June 15, 2023
- AstraZeneca Launches Sales Unit Dedicated to GI Cancer as Imfinzi Expands Label
June 14, 2023
- AbbVie Goes Solo in Humira Marketing and Promotion in Japan
June 14, 2023
- Argenx Makes World’s 1st Filing in Japan for Vyvgart’s ITP Use
June 14, 2023
- Keytruda Filed for Biliary Tract Cancer in Japan
June 14, 2023
- Lilly, Mitsubishi Tanabe Roll Out Mounjaro’s High-Dose Versions
June 13, 2023
- US District Court Rejects Claim for Myrbetriq Patent Infringement, Astellas to Challenge Ruling
June 13, 2023
- Shionogi Kicks Off Global PEP Study of Xocova; NDA for Full Approval Filed in Japan
June 12, 2023
- Astellas Files Zolbetuximab for CLDN18.2-Positive Gastric Cancer in Japan
June 12, 2023
- ASKA, RaQualia Wind Up Ion Channels Collab
June 12, 2023
- FDA Advisors Back Full Approval of Eisai’s Alzheimer’s Med
June 12, 2023
- AstraZeneca Crowned in Foreign Pharma Ranking for 2nd Year Straight, Followed by MSD
June 9, 2023
- Ceolia Pharma’s Comlex Otic Solution Now Available in Japan
June 9, 2023
- Takeda Rolls Out Low-Dose Form of SBS Therapy Revestive in Japan
June 9, 2023
- Lecanemab Filed for Approval in South Korea: Eisai/Biogen
June 9, 2023
- Astellas Grabs Rights to Kate’s XLMTM Gene Therapy
June 9, 2023
- Opdivo Top-Seller Drug in Japan for 17 Months on End: Encise
June 8, 2023
- Japan Ethical Drug Sales Up 1.4% in April: Crecon
June 8, 2023
- Enhertu Nets Favorable Data in Pan-Tumor Trial for HER2 Solid Cancers
June 7, 2023
ページ
Earlier this month, the Ministry of Finance (MOF) unveiled a long list of social security proposals towards the FY2025 budgeting,…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…